A review from the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has reported that “orphan designations” (OD) on inherited retinal… Read More »The EMA Committee for Orphan Medicinal Products (COMP) propose a new approach to Orphan Designations (OD) on inherited retinal degenerations (IRDs).
The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) have announced a positive opinion for the granting of a marketing authorisation for… Read More »EMA (European Medicines Agency) approves authorisation of ocular formulation of bevacizumab AMD.
Researchers at the Wilmer Eye Institute, Johns Hopkins University, Baltimore, has reported that an estimate cohort of one-third of inherited retinal dystrophy (IRD) patients had… Read More »A prospective cohort study of IRD patients report the frequency and distributions of ophthalmic surgical procedures at the Wilmer Eye Institute.
Researchers at Newcastle University and Sunderland Eye Infirmary, UK, have reported that, to date, there is “no evidence that complement inhibition with any agent improves… Read More »A systematic review on complement inhibitors suggests no evidence to date from functional endpoints in advanced AMD.
The MACUSTAR consortium, supported by the Innovative Medicines Initiative, has received a further support of funding from industry partners Bayer, Novartis and Roche, agreed to… Read More »The MACUSTAR consortium on AMD has received a further support of funding of €3M and an extension for work until 2027.
Researchers at the Hawaiian Eye and Retina meeting in Maui has reported positive 6-month results for RGX-314, for the treatment of wet AMD, using a… Read More »Phase 2 interim data for RGX-314 treatment for wet AMD reports stable BCVA and CRT at six months.
Researchers at the University of Nevada, Reno School of Medicine and the Department of Ophthalmology, Weill Cornell Medical College, New York-Presbyterian Hospital, has published safety… Read More »Phase 1 study results published in the Lancet report stable vision following a single dose gene therapy encoding anti-VEGF protein.
Researchers at UCL and Moorfields Eye Hospital, UK, have reported clinical research using artificial intelligence (AI) tools to identify at-risk neonates of retinopathy of prematurity… Read More »Clinical research at UCL and Moorfields on AI tools to identify at-risk neonates of retinopathy of prematurity (ROP).
A recent update on phase 2 clinical research of a novel treatment for patients of Stargardt disease has reported a positive primary end-point slowing the… Read More »Clinical research on a novel oral therapy for Stargardt disease suggests uses a deuterated form of vitamin A.
Researchers at the Institute for Vision Research, University of Iowa, USA, and Ophthalmology and Visual Sciences, Duke-NUS Graduate Medical School, Singapore, have reported a publication… Read More »Research on clinical trial outcomes for XLRS have proposed prolonged trial periods in order to assess disease stabilization.
